Hypoactive Sexual Desire Disorder (HSDD) is a complex sexual dysfunction characterized by a lack of sexual desire. Many psychologists claim that hypoactive sexual desire disorder is caused by distress or other psychological and interpersonal difficulties that are sometimes a symptom of other mental disorders. The various kinds of hypoactive sexual desire disorders include partner-specific HSDD or generalized HSDD, and can either be lifelong or recently acquired.
Although treatment is generally found insufficient in cases of lifelong hypoactive sexuality disorder, patients with acquired hypoactive sexuality disorder or those suffering from some kind of distress can be helped by the number of hypoactive sexual desire disorder treatments available.
Using sex hormones as well as neurotransmitters are considered the best hypoactive sexuality disorder treatment methods currently available. Some top hypoactive sexuality disorder drugs currently available include:
- Intrinsa: Intrinsa® is a hypoactive sexuality disorder drug. This testosterone sex hormone patch is produced by Proctor & Gamble for treating female sexual dysfunction. Some of the conditions that Intrinsa treats include problems with having orgasms, genital pain, arousal, and desire. The patch increases a woman’s libido, especially for menopausal women or those who are surgically menopausal. This hypoactive sexual disorder medication, though it has not found fast-track approval from the FDA, aims to increase and treat the libido of women by targeting the problem of low sexual stamina.
- Viagra: Viagra® is the trade name of sildenafil citrate, a much discussed hypoactive sexual disorder medication for men. This HSDD treatment enables men to gain proper erectile function, while increasing their arousal as well as libido.
- Levitra: Levitra® is also a very good hypoactive sexual disorder treatment option for men. It is also available under other trade names like Vivanza® in Europe.
- Flibanserin: This is a new nonhormonal hypoactive sexual disorder treatment for women who are premenopausal and suffer from hypoactive sexual desire disorder or HSDD. Flibanserin® affects the receptors of the brain that can help restore the libido in premenopausal women.
- Organon: Organon® is a hypoactive sexual desire disorder implant commonly used in Australia. It is manufactured by Organon International, now part of Schering-Plough. This testosterone implant can be surgically inserted. Its lasts for three to six months. The implant should be replaced every six months. It is considered a highly effective drug for the treatment of hypoactive sexuality disorder or HSDD.
© Newsmax. All rights reserved.